^
Association details:
| Biomarker: | Chr amplification(1)(q21) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + lisaftoclax (APG-2575) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models
Published date:
11/04/2020
Excerpt:
...we combined APG-2575 with lenalidomide. Cell death was increased in the combination groups compared with single agent, and it was dose-dependent (Figure 1b).Similar enhanced antiproliferative activity was confirmed in RPMI 8226 cell line, which carries 1q21 amplification (Figure 1c).
